Industry Spotlight: EuMentis Therapeutics
EuMentis is evaluating other neuropsychiatric conditions that involve glutamate or dopamine imbalance for low-trapping NMDA antagonists, EM-221, or other novel compounds derived from its platforms to treat symptoms of pediatric neuropsychiatric disorders such as Tourette Syndrome and ASD.
Developing a Noncompetitive NMDA Antagonist for Autism Spectrum Disorder
EuMentis is developing noncompetitive, low-trapping glutamate antagonists designed to inhibit receptors on neurons that are overly active. EuMentis is combining this clinically-validated approach with novel imaging technology to identify patients with ASD who are most likely to benefit.